Lupus & antiphospholipid syndrome
Incidence ofPneumocystis jiroveciiPneumonia and Prophylaxis-Associated Adverse Events Among Patients With Systemic Lupus Erythematosus
Authors' conclusion
PJP rarely affects patients with SLE undergoing therapy with MMF and/or CYC; prophylaxis against PJP is associated with adverse events.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) (≥2 ICD-9-CM/ICD-10-CM codes ≥30 days apart) who were new users of mycophenolate mofetil (MMF) and/or CYC
- Participants
- 6,017 patients2,752 person-years
- Exposure
- Pneumocystis jirovecii pneumonia (PJP) prophylaxis vs no prophylaxis
- Outcome
- Incidence of PJP
- Follow-up
- First 6 months of therapy
Methodological detailsTriNetX database, Cox proportional hazards regression
- TriNetX database
- Cox proportional hazards regression
Main finding
As reported in the abstract
PJP incidence
PJP cases over 2752 person-years (PYs) (one received prophylaxis)
5
Incidence rate, cases/1000 PYs
1.8
Observational data: associations, not effects.
Safety
| Outcome | Estimate | |
|---|---|---|
| Adverse events with prophylaxis (adjusted)Prophylaxisvs No prophylaxisAdjusted analysis | HR (neutropenia) 2.5 (95% CI 1.4–4.4) | |
| Adverse events with prophylaxis (adjusted)Prophylaxisvs No prophylaxisAdjusted analysis | HR (leukopenia) 1.9 (95% CI 1.3–2.8) | |
| Adverse events with prophylaxis (adjusted)Prophylaxisvs No prophylaxisAdjusted analysis | HR (nephropathy) 1.7 (95% CI 1.4–2.1) | |
| Adverse events with prophylaxis (adjusted)Prophylaxisvs No prophylaxisAdjusted analysis | HR (hyperkalemia) 1.4 (95% CI 0.9–2.0) | |
| 0.20.5125Ratio (log scale) |
Original publication
Incidence ofPneumocystis jiroveciiPneumonia and Prophylaxis-Associated Adverse Events Among Patients With Systemic Lupus Erythematosus. J Rheumatol. Published 1 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →